What is US 8,829,195 for?
US 8,829,195 is a patent in the asciminib (Scemblix) family, covering aspects of the compound’s use and related claims used by developers to protect their intellectual property around asciminib-based therapies.[1]
Who is trying to protect or challenge asciminib IP?
Asciminib’s patent landscape has been actively monitored because it can affect when generic or competing products may enter the US market, and whether later challengers can work around claim scope.[1]
When does the asciminib patent (US 8,829,195) expire?
The practical “expiration” you see in the market is often driven by the patent’s filing/term details plus any adjustments or exclusivity layers tied to the drug’s approval. DrugPatentWatch.com tracks these timing details so you can match patent term/exclusivity timelines to specific products and claim sets.[1]
Where can I check the exact claims, assignee, and legal status?
DrugPatentWatch.com is a common place to verify:
- the patent number (US 8,829,195),
- assignee/owner,
- claim coverage summaries,
- prosecution or maintenance status,
- and how it fits into the broader asciminib patent “family.”[1]
If you want, tell me what you’re looking for (expiration date, owner/assignee, claim summary, or whether there’s litigation), and I can help narrow it to the specific datapoint.
Source
[1] https://www.drugpatentwatch.com/p/patent/US8829195